# Seattle Children's Hospital: Phase 1 study in Acute Myeloid Leukemia, Acute Myeloid Leukaemia Recurrent (20 participants)

**Score:** 55/100

| Field | Value |
|---|---|
| Sponsor | Seattle Children's Hospital |
| Sponsor type | Academic and hospital |
| Study | A Study of CLEC2A CAR T for Pediatric and Adult Patients With Relapsed or Refractory AML |
| NCT ID | NCT07905027 |
| Phase | Phase 1 |
| Status | not yet recruiting |
| Conditions | Acute Myeloid Leukemia; Acute Myeloid Leukaemia Recurrent; Acute Myeloid Leukaemia Refractory |
| Intervention types | biological |
| Target enrollment | 20 |
| Site countries | United States |
| Posted | 2026-10-29 |
| Planned start | 2026-11 |
| Event | Newly registered study |
| Event date | 2026-10-29 |

## Why this score
- Posted in the last two weeks.
- Not yet recruiting: vendors still being chosen.

Source: ClinicalTrials.gov (U.S. National Library of Medicine) API v2 (https://clinicaltrials.gov/study/NCT07905027). Last refreshed: 2026-11-04T06:04:38.232Z.
From public ClinicalTrials.gov registrations. Sponsor and study level only: we never list investigators, contacts or participants. A registration describes a planned study and can change. Status changes are read from each study's current status, actual dates and latest posted update, not a full change history, so an update can be a correction rather than a new change. Verify on ClinicalTrials.gov.